Vitaros (alprostadil), indicated to treat erectile dysfunction (ED) is applied directly as a cream that boosts blood flow. According to the collaboration deal, Abbott will commercialize and market
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2′-methyl guanosine, and is currently being developed under a partial clinical hold. The randomized, double-blind parallel group Phase IIb
Polyplasdone PVPP is a synthetic polymer used as a tablet disintegrant and drug dissolution aid in a many over-the-counter and prescription drug products. The company is likely to
Relovair is a once-daily inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combination treatment, comprising fluticasone furoate and vilanterol (FF/VI), currently in development for the treatment of COPD and asthma. The
BioReliance provides services including biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics. BioReliance’s service is believed to help facilitate biological drug development, manufacturing and commercialization
In the study, 18 patients with type 2 diabetis received single doses of either LX4211 (400 mg), sitagliptin (100 mg) or LX4211 plus sitagliptin on days 1, 8,
Ingenuity Variant Analysis is a web application that enables researchers to identify causal variants from human resequencing data in a short time period using known information about the
The company’s molecularly-guided treatment decision support solutions will initially be available for use in oncology. The tools also integrate molecular data including whole genome sequences with clinical information
USPTO granted two patents which provide intellectual property protection for methods relating to the company’s products and technology, while the European Patent Office granted a patent providing coverage
Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.